Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

INVO Fertility (IVF) Shares Outstanding (Diluted Average) (2016 - 2025)

INVO Fertility (IVF) has disclosed Shares Outstanding (Diluted Average) for 15 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 1216.23% to $1.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.4 million, a 1216.23% increase, with the full-year FY2024 number at $309539.0, up 159.54% from a year prior.
  • Shares Outstanding (Diluted Average) was $1.4 million for Q3 2025 at INVO Fertility, up from $397440.0 in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $12.1 million in Q1 2022 to a low of $100276.0 in Q2 2024.
  • A 5-year average of $3.3 million and a median of $622507.0 in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): plummeted 94.83% in 2023, then skyrocketed 1216.23% in 2025.
  • INVO Fertility's Shares Outstanding (Diluted Average) stood at $10.6 million in 2021, then plummeted by 94.3% to $606130.0 in 2022, then tumbled by 80.32% to $119264.0 in 2023, then skyrocketed by 159.54% to $309539.0 in 2024, then skyrocketed by 359.02% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for IVF's Shares Outstanding (Diluted Average) are $1.4 million (Q3 2025), $397440.0 (Q2 2025), and $1.4 million (Q1 2025).